PHOTO
Amman, Jordan: Continuing its efforts to empower clinicians and patients in their fight against breast cancer, GE Healthcare marked the Middle East launch of its revolutionary Invenia Automated Breast Ultrasound (ABUS) 2.0 at the Jordan Breast Cancer Program (JBCP) multi-disciplinary workshop.
The only FDA-approved ultrasound supplemental breast screening technology, specifically designed for detecting cancer in dense breast tissue, the Invenia ABUS 2.0, when used in addition to mammography, can improve breast cancer detection by 37.5 percent over mammography alone.[1] Its use is cleared in all countries in the region.
Held under the leadership of the King Hussein Cancer Foundation (KHCF), the JBCP workshop was focused on increasing public awareness on breast cancer and improving the quality of diagnostic services. The launch of Invenia ABUS 2.0 at the event underlines the commitment of GE Healthcare to engage leading medical practitioners in the region with the latest technology that will help them advocate efficient screening for early diagnosis and care of breast cancer.
Dense breast tissue is one of the common risk factors for developing breast cancer. Breast density is a measurement of the amount of fatty tissue versus the amount of fibrous tissue in the breast. Both cancer and dense tissue appear white on a mammogram, so looking for tumors in women with dense breasts can be like looking for a snowball in a snowstorm. Because of this, tumors are often unseen – or “masked” – on mammography exams.
Proposing a solution for dense breast screening, thereby increasing diagnostic efficiency, the Invenia ABUS 2.0 ensures a more pleasant patient experience and helps diagnosis breast cancer at the earliest stage possible.
“ABUS can help clinicians detect significantly more cancers than mammography alone, especially in women with dense breasts,” says Dr. Hisham Youssef, Ultrasound General Manager at GE Healthcare in the Eastern Growth Markets. “With the Middle East reporting increasing incidence of breast cancer2, it is important to continue the concerted efforts to raise breast cancer awareness through such workshops. As breast ultrasound technology continues to advance, we are investing to continually improve image quality, workflow and patient comfort – all of which contribute to early detection and improved outcomes.”
Dr. Reem Al-Ajlouni, Director of JBCP, said: “One of the primary aims of the Jordan Breast Cancer Program has been to raise awareness about the new advances in breast cancer screening, and to underline the importance of early detection that promotes better diagnosis and aftercare. The new innovation by GE Healthcare will enable medical practitioners to address some of the key challenges they face, especially with regard to dense breast screening, and hopefully will help them achieve better diagnosis.”
Dr. Laila Tahoun, Director of Breast Imaging Unit, King Hussein Head Cancer Center, said: “We have continuously focused on promoting breast cancer screening as a first and important step to address the growing challenge of breast cancer in the region. With the new technology now made available by GE Healthcare, women are assured of not only accurate diagnosis but also an improved patient comfort during the examination.”
Prof. Dr. Laszlo Tabar, Professor Emeritus of Radiology, Faculty of Medicine at Uppsala University in Sweden, added: “In the fight against breast cancer, advances in diagnostic technology plays a key role, as they make identifying the condition easier. Imaging the breasts of women with dense fibroglandular tissue is a considerable challenge. Adding the FDA-approved automated breast ultrasound to full field digital mammography is a proven solution, resulting in detecting more than 30% of invasive breast cancers.”
Launched in 2014, Invenia ABUS has been installed at hundreds of facilities around the world, including in the Middle East. The Invenia ABUS 2.0 builds on its predecessor to enhance the exam experience for both operators and patients, including new features that further customize the exam based on the patient’s body:
- Efficient exams: The powerful cSound™ Imageformer, a software-based graphics processor, provides a reproducible and operator-independent acquisition method to achieve consistent, high quality results. cSound imaging allows significantly more data to be collected and used to create every image. Traditional hand-held ultrasound parameters such as focal zones and gain are automatically optimized. No image manipulation is required, so that high image quality is consistent from operator to operator with the touch of a button.
- Improving the patient experience: The gentle shape of the Reverse Curve™ transducer follows the natural contour of the breast, providing patient comfort, thorough contact and helping ensure comprehensive coverage. The 15 cm large field-of-view transducer is easy to position and maintains even compression while scanning. Since no two women are identical, exams can be customized with programmable scan protocols, adjustable scan depths and compression levels. With the touch of a button, the operator can also shorten scan time once breast tissue acquisition is complete.
-Ends-
About GE Healthcare
GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps improve outcomes more efficiently for patients, healthcare providers, researchers and life sciences companies around the world. Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website www.gehealthcare.com for more information.
For further information:
Nader Abou-Guendia Kelly Home | Nivine William
Communications -
Eastern Growth Markets, GE Healthcare ASDA’A BCW
T: +9714 429 6588 | M: +97155 980 4206 kelly.home@bcw-global.com
nader.abou-guendia@ge.com nivine.william@bcw-global.com
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
